Concepedia

Adrian Bot

AB

Statistics

Publications

89

Citations

15.3K

H-Index

45

Active since

1996

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

Moffitt Cancer Center

Dana-Farber Cancer Institute

Kite (United States)

Stanford University

Adrian Bot is an author at The University of Texas MD Anderson Cancer Center specializing in immunology, life sciences, and immunotherapy.

ORCID

Publications per year

1996–2025

89

Publications

89

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett et al. · New England Journal of Medicine · 2017 · 5.9K citations · Full text

, , +16

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial

Frederick L. Locke, Armin Ghobadi, Caron A. Jacobson et al. · The Lancet Oncology · 2018 · 2.3K citations

, , +12

Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma

Frederick L. Locke, Sattva S. Neelapu, Nancy L. Bartlett et al. · Molecular Therapy · 2017 · 619 citations · Full text

, , +17

Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels

James N. Kochenderfer, Robert Somerville, Tangying Lu et al. · Journal of Clinical Oncology · 2017 · 561 citations

, , +17

Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma

Frederick L. Locke, John M. Rossi, Sattva S. Neelapu et al. · Blood Advances · 2020 · 455 citations · Full text

, , +17

1–5 of 89